CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR
Authors:
- T Watkins-RiedelTWT Watkins-Riedel
- Ht GreinixHGHt Greinix
- W RabitschWRW Rabitsch
- H LoidoltHLH Loidolt
- F KeilFKF Keil
- M MitterbauerMMM Mitterbauer
- P KalhsPKP Kalhs
- 1 October 2001
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (8) , 765-768
Abstract
We prospectively monitored 74 consecutive allogeneic and 50 autologous patients after bone marrow/stem cell transplantation from May 1999 to October 2000 at our institution with quantitative CMV PCR and pp65 antigen assay once weekly from conditioning therapy to days 120 and 80 after transplantation, respectively. Written informed consent was obtained from every patient. CMV prophylaxis consisted of acyclovir during transplant. Additionally all patients received only platelet products from CMV-negative donors. In the case of CMV infection preemptive therapy with gancyclovir was applied. In the case of CMV disease high-dose immunoglobulin was given as well. In the allogeneic setting 16 out of 74 (22%) patients developed a positive PCR. Seven episodes of a positive pp65 antigen assay occurred in six allograft recipients. In the autologous setting no positive assay was found during the whole observation period. Additionally, in 6/16 patients a lymphoproliferative assay was performed during CMV infection. Two patients showed a positive (15 and 5.4) and four a negative (2,1.6,1,1.8) stimulation index.Keywords
This publication has 15 references indexed in Scilit:
- Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infectionBone Marrow Transplantation, 2001
- Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infectionBone Marrow Transplantation, 2000
- Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell TransplantationBlood, 1999
- Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV diseaseBone Marrow Transplantation, 1997
- Quantitation of human cytomegalovirus DNA in bone marrow transplant recipientsBritish Journal of Haematology, 1995
- Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantationBlood, 1995
- Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytesJournal of Medical Virology, 1988
- Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantationBlood, 1988
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986